1
|
Wallander K, Öfverholm I, Yingbo L, Haglund C, Chellappa V, Tsagkozis P, Hesla A, Papakonstantinou A, Bränström R, Wirta V, Lindberg J, Haglund de Flon F. 58P Evaluating the impact of WGTS in routine diagnostics of bone and soft tissue tumors. ESMO Open 2023. [DOI: 10.1016/j.esmoop.2023.101095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
2
|
Micoli C, Crippa A, Discacciati A, Vigneswaran H, Palsdottir T, Clements M, Aly M, Adolfsson J, Fredrik W, Wiklund P, James T, Lindberg J, Grönberg H, Egevad L, Nordström T, Eklund M. The Stockholm3 prostate cancer screening trial (STHLM3): An interim analysis of mortality results after 6.5 years of follow-up. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00930-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
3
|
Gurjar M, Lindberg J, Abel E, Olsson C. PD-0794 Effectiveness of Dynamic Prioritization for patient scheduling: A Discrete-Event Simulation Model. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07073-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
4
|
Lindberg J, De Laere B, Crippa A, Eklund M, Grönberg H. ProBio: An outcome-adaptive, multi-arm, open-label, multiple assignment randomised controlled biomarker-driven trial in patients with metastatic castration-resistant prostate cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz248.053] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
5
|
De Laere B, Crippa A, Ghysel C, Ost P, Rajan P, Eklund M, Dirix L, Grönberg H, Lindberg J. Elevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz239.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
6
|
Lindberg J, Holmström P, Hallberg S, Björk-Eriksson T, Olsson C. Simulating the Radiation Therapy Process: An Analytical Approach to Enable Quantification of Patient Inflows. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
7
|
Lindberg J, Holmström P, Hallberg S, Björk-Eriksson T, Olsson C. Healthcare Professionals’ Views on Work Related Issues at Swedish Radiotherapy Departments. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1511] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
8
|
Lindberg J, Holmström P, Hallberg S, Björk-Eriksson T, Olsson C. PO-1129 An analytical approach to aggregate patient workflows for system dynamics modelling of radiotherapy. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31549-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
9
|
Ross-Adams H, Lamb AD, Dunning MJ, Halim S, Lindberg J, Massie CM, Egevad LA, Russell R, Ramos-Montoya A, Vowler SL, Sharma NL, Kay J, Whitaker H, Clark J, Hurst R, Gnanapragasam VJ, Shah NC, Warren AY, Cooper CS, Lynch AG, Stark R, Mills IG, Grönberg H, Neal DE. Corrigendum to "Integration of Copy Number and Transcriptomics Provides Risk Stratification in Prostate Cancer: A Discovery and Validation Cohort Study" [EBioMedicine 2 (9) (2015) 1133-1144]. EBioMedicine 2017; 17:238. [PMID: 28292578 PMCID: PMC5680481 DOI: 10.1016/j.ebiom.2017.03.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Affiliation(s)
- H Ross-Adams
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
| | - A D Lamb
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK; Department of Urology, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK; Academic Urology Group, University of Cambridge, Cambridge, CB2 0QQ, UK.
| | - M J Dunning
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
| | - S Halim
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
| | - J Lindberg
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
| | - C M Massie
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
| | - L A Egevad
- Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
| | - R Russell
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
| | - A Ramos-Montoya
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
| | - S L Vowler
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
| | - N L Sharma
- Nuffield Department of Surgical Sciences, University of Oxford, Roosevelt Drive, Oxford, UK.
| | - J Kay
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK; Molecular Diagnostics and Therapeutics Group, University College London, WC1E 6BT, UK.
| | - H Whitaker
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK; Molecular Diagnostics and Therapeutics Group, University College London, WC1E 6BT, UK.
| | - J Clark
- University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK.
| | - R Hurst
- University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK.
| | - V J Gnanapragasam
- Department of Urology, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK; Academic Urology Group, University of Cambridge, Cambridge, CB2 0QQ, UK.
| | - N C Shah
- Department of Urology, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK.
| | - A Y Warren
- Department of Pathology, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK.
| | - C S Cooper
- University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK.
| | - A G Lynch
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
| | - R Stark
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
| | - I G Mills
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK; Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, N-0318 Oslo, Norway; Department of Molecular Oncology, Institute of Cancer Research, Oslo University Hospitals, N-0424 Oslo, Norway; Prostate Cancer UK/Movember Centre of Excellence for Prostate Cancer Research, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, UK.
| | - H Grönberg
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
| | - D E Neal
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK; Department of Urology, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK.
| | | |
Collapse
|
10
|
Green MA, Willis M, Fernandez-Kong K, Reyes S, Linkhart R, Johnson M, Thorne T, Lindberg J, Kroska E, Woodward H. A Controlled Randomized Preliminary Trial of a Modified Dissonance-Based Eating Disorder Intervention Program. J Clin Psychol 2017; 73:1612-1628. [DOI: 10.1002/jclp.22468] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2016] [Revised: 01/17/2017] [Accepted: 01/29/2017] [Indexed: 11/10/2022]
Affiliation(s)
- M. A. Green
- Cornell College Body Dissatisfaction and Eating Disorder Research Laboratory
| | - M. Willis
- Cornell College Body Dissatisfaction and Eating Disorder Research Laboratory
| | - K. Fernandez-Kong
- Cornell College Body Dissatisfaction and Eating Disorder Research Laboratory
| | - S. Reyes
- Cornell College Body Dissatisfaction and Eating Disorder Research Laboratory
| | - R. Linkhart
- Cornell College Body Dissatisfaction and Eating Disorder Research Laboratory
| | - M. Johnson
- Cornell College Body Dissatisfaction and Eating Disorder Research Laboratory
| | - T. Thorne
- Cornell College Body Dissatisfaction and Eating Disorder Research Laboratory
| | | | | | | |
Collapse
|
11
|
Scott E, Adolfsson J, Aly M, Nordström T, Wiklund P, Brandberg Y, Thompson J, Wiklund F, Lindberg J, Clements M, Egevad L, Eklund M. Prostate cancer screening in men aged 50 to 69 years (STHLM3): A prospective population-based diagnostic study. Grönberg H, Adolfsson J, Aly M, Nordström T, Wiklund P, Brandberg Y, Thompson J, Wiklund F, Lindberg J, Clements M, Egevad L, Eklund M.Lancet Oncol. 2015 Dec;16(16):1667-76. [Epub 2015 Nov 10]. doi: 10.1016/S1470-2045(15)00361-7. Urol Oncol 2017; 35:120. [PMID: 28215847 DOI: 10.1016/j.urolonc.2016.03.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2016] [Accepted: 03/15/2016] [Indexed: 11/20/2022]
Abstract
BACKGROUND The prostate-specific antigen (PSA) test is used to screen for prostate cancer but has a high false-positive rate that translates into unnecessary prostate biopsies and overdiagnosis of low-risk prostate cancers. We aimed to develop and validate a model to identify high-risk prostate cancer (with a Gleason score of at least 7) with better test characteristics than that provided by PSA screening alone. METHODS The Stockholm 3 (STHLM3) study is a prospective, population-based, paired, screen-positive, diagnostic study of men without prostate cancer aged 50 to 69 years randomly invited by date of birth from the Swedish Population Register kept by the Swedish Tax Agency. Men with prostate cancer at enrolment were excluded from the study. The predefined STHLM3 model (a combination of plasma protein biomarkers [PSA, free PSA, intact PSA, hK2, MSMB, MIC1], genetic polymorphisms [232 SNPs], and clinical variables [age, family, history, previous prostate biopsy, prostate exam]), and PSA concentration were both tested in all participants enrolled. The primary aim was to increase the specificity compared with PSA without decreasing the sensitivity to diagnose high-risk prostate cancer. The primary outcomes were number of detected high-risk cancers (sensitivity) and the number of performed prostate biopsies (specificity). The STHLM3 training cohort was used to train the STHLM3 model, which was prospectively tested in the STHLM3 validation cohort. Logistic regression was used to test for associations between biomarkers and clinical variables and prostate cancer with a Gleason score of at least 7. This study is registered with ISCRTN.com, number ISRCTN84445406. FINDINGS The STHLM3 model performed significantly better than PSA alone for detection of cancers with a Gleason score of at least 7 (P<0.0001), the area under the curve was 0·56 (95% CI: 0·55-0·60) with PSA alone and 0·74 (95% CI: 0·72-0·75) with the STHLM3 model. All variables used in the STHLM3 model were significantly associated with prostate cancers with a Gleason score of at least 7 (P<0·05) in a multiple logistic regression model. At the same level of sensitivity as the PSA test using a cutoff of≥3ng/ml to diagnose high-risk prostate cancer, use of the STHLM3 model could reduce the number of biopsies by 32% (95% CI: 24-39) and could avoid 44% (35-54) of benign biopsies. INTERPRETATION The STHLM3 model could reduce unnecessary biopsies without compromising the ability to diagnose prostate cancer with a Gleason score of at least 7, and could be a step towards personalised risk-based prostate cancer diagnostic programmes. FUNDING Stockholm County Council (Stockholms Läns Landsting).
Collapse
|
12
|
Czene K, Ivansson E, Klevebring D, Tobin NP, Lindström LS, Holm J, Prochazka G, Hilliges C, Palmgren J, Törnberg S, Humphreys K, Hartman J, Frisell J, Rantalainen M, Lindberg J, Hall P, Bergh J, Grönberg H, Li J. Abstract P2-03-03: Molecular differences between screen-detected and interval breast cancers are largely explained by PAM50 subtypes. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-03-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose:Interval breast cancer is of clinical interest as it exhibits an aggressive phenotype and evades detection by screening mammography. A comprehensive picture of somatic changes that drive tumors to become symptomatic in the screening interval can improve understanding of the biology underlying these aggressive tumors.
Experimental design:Initiated in April 2013, Clinical Sequencing of Cancer in Sweden (Clinseq) is a scientific and clinical platform for the genomic profiling of cancer. The breast cancer pilot study consisted of women diagnosed with breast cancer between 2001-2012 in the Stockholm/Gotland regions. A subset of 318 breast tumors were sequenced, of which 113 were screen-detected and were 60 interval cancers.We applied targeted deep-sequencing of cancer-related genes, low-pass whole-genome sequencing and RNA-sequencing technology to characterize somatic differences in the genomic and transcriptomic architecture by interval cancer status. Mammographic density and PAM50 molecular subtypes were considered.
Results:In the crude analyses, TP53, PPP1R3A, and KMT2B were significantly more frequently mutated in interval cancers than in screen-detected cancers. Acquired somatic copy number aberrations with a frequency difference of at least 15% between the two groups included gains in 17q23-q25.3 and losses in 16q24.2. Gene expression analysis identified 447 significantly differentially expressed genes, of which 120 were replicated in an independent microarray dataset. After adjusting for PAM50, most differences were no longer significant.
Conclusions: Molecular differences by interval cancer status were observed, but they were largely explained by PAM50 subtypes. This work offer new insights into the biological differences between the two tumor groups.
Translational relevance: Although screen-detected cancers are biologically distinct from interval cancers in terms of somatic mutations, copy number aberrations and gene expression, most of the differences are no longer significant after adjusting for breast cancer intrinsic subtypes (PAM50). We also show that the molecular differences appear to form a spectrum from less aggressive (screen-detected) to more aggressive (interval) manifestations of the disease, which can be characterized by PAM50 subtypes, namely, luminal A, luminal B, HER2-enriched and basal-like, in that order. This work clarifies the picture on what type of breast cancer we are likely to identify through population-based screening, and what type of cancer we are likely to miss. Current knowledge of PAM50 subtype-specific risk factors need to be expanded as our findings might influence how we screen women with a higher risk of basal-like breast cancer for example, beyond known risk groups BRCA1 mutation carriers and women of African-American descent.
Citation Format: Czene K, Ivansson E, Klevebring D, Tobin NP, Lindström LS, Holm J, Prochazka G, Hilliges C, Palmgren J, Törnberg S, Humphreys K, Hartman J, Frisell J, Rantalainen M, Lindberg J, Hall P, Bergh J, Grönberg H, Li J. Molecular differences between screen-detected and interval breast cancers are largely explained by PAM50 subtypes [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-03-03.
Collapse
Affiliation(s)
- K Czene
- Karolinska Institutet, Stockholm, Sweden; Stockholm-Gotland Regional Cancer Centre, Stockholm, Sweden; Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - E Ivansson
- Karolinska Institutet, Stockholm, Sweden; Stockholm-Gotland Regional Cancer Centre, Stockholm, Sweden; Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - D Klevebring
- Karolinska Institutet, Stockholm, Sweden; Stockholm-Gotland Regional Cancer Centre, Stockholm, Sweden; Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - NP Tobin
- Karolinska Institutet, Stockholm, Sweden; Stockholm-Gotland Regional Cancer Centre, Stockholm, Sweden; Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - LS Lindström
- Karolinska Institutet, Stockholm, Sweden; Stockholm-Gotland Regional Cancer Centre, Stockholm, Sweden; Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - J Holm
- Karolinska Institutet, Stockholm, Sweden; Stockholm-Gotland Regional Cancer Centre, Stockholm, Sweden; Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - G Prochazka
- Karolinska Institutet, Stockholm, Sweden; Stockholm-Gotland Regional Cancer Centre, Stockholm, Sweden; Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - C Hilliges
- Karolinska Institutet, Stockholm, Sweden; Stockholm-Gotland Regional Cancer Centre, Stockholm, Sweden; Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - J Palmgren
- Karolinska Institutet, Stockholm, Sweden; Stockholm-Gotland Regional Cancer Centre, Stockholm, Sweden; Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - S Törnberg
- Karolinska Institutet, Stockholm, Sweden; Stockholm-Gotland Regional Cancer Centre, Stockholm, Sweden; Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - K Humphreys
- Karolinska Institutet, Stockholm, Sweden; Stockholm-Gotland Regional Cancer Centre, Stockholm, Sweden; Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - J Hartman
- Karolinska Institutet, Stockholm, Sweden; Stockholm-Gotland Regional Cancer Centre, Stockholm, Sweden; Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - J Frisell
- Karolinska Institutet, Stockholm, Sweden; Stockholm-Gotland Regional Cancer Centre, Stockholm, Sweden; Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - M Rantalainen
- Karolinska Institutet, Stockholm, Sweden; Stockholm-Gotland Regional Cancer Centre, Stockholm, Sweden; Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - J Lindberg
- Karolinska Institutet, Stockholm, Sweden; Stockholm-Gotland Regional Cancer Centre, Stockholm, Sweden; Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - P Hall
- Karolinska Institutet, Stockholm, Sweden; Stockholm-Gotland Regional Cancer Centre, Stockholm, Sweden; Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - J Bergh
- Karolinska Institutet, Stockholm, Sweden; Stockholm-Gotland Regional Cancer Centre, Stockholm, Sweden; Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - H Grönberg
- Karolinska Institutet, Stockholm, Sweden; Stockholm-Gotland Regional Cancer Centre, Stockholm, Sweden; Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - J Li
- Karolinska Institutet, Stockholm, Sweden; Stockholm-Gotland Regional Cancer Centre, Stockholm, Sweden; Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| |
Collapse
|
13
|
Rutegård M, Palmqvist R, Stenling R, Lindberg J, Rutegård J. Efficiency of Colorectal Cancer Surveillance in Patients with Ulcerative Colitis: 38 Years' Experience in a Patient Cohort from a Defined Population Area. Scand J Surg 2016; 106:133-138. [PMID: 27431978 DOI: 10.1177/1457496916659224] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
BACKGROUND AND AIMS Ulcerative colitis increases the risk of developing colorectal cancer. Colonoscopic surveillance is recommended although there are no randomized trials evaluating the efficacy of such a strategy. This study is an update of earlier studies from an ongoing colonoscopic surveillance program. MATERIAL AND METHODS All patients with ulcerative colitis were invited to the surveillance program that started in 1977 at Örnsköldsvik Hospital, located in the northern part of Sweden. Five principal endoscopists performed the colonoscopies and harvested mucosal sampling for histopathological evaluation. Some 323 patients from the defined catchment area were studied from 1977 to 2014. At the end of the study period, 130 patients, including those operated on, had had total colitis for more than 10 years. RESULTS In total, 1481 colonoscopies were performed on 323 patients during the study period without any major complications. In all, 10 cases of colorectal cancer were diagnosed in 9 patients, of whom 1 died from colorectal cancer. The cumulative incidence of colorectal cancer was 1.4% at 10 years, 2.0% at 20 years, 3.0% at 30 years, and 9.4% at 40 years of disease duration, respectively. The standardized colorectal cancer incidence ratio was 3.01 (95% confidence interval: 1.42-5.91). Major surgery was performed on 65 patients; for 20 of these, the indication for surgery was dysplasia or colorectal cancer. Panproctocolectomy was performed in 43 patients. CONCLUSION This study supports that colonoscopic surveillance is a safe and effective long-term measure to detect dysplasia and progression to cancer. The low numbers of colorectal cancer-related deaths in our study suggest that early detection of neoplasia and adequate surgical intervention within a surveillance program may reduce colorectal cancer mortality in ulcerative colitis patients.
Collapse
Affiliation(s)
- M Rutegård
- 1 Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden
| | - R Palmqvist
- 2 Department of Medical Biosciences, Umeå University, Umeå, Sweden
| | - R Stenling
- 2 Department of Medical Biosciences, Umeå University, Umeå, Sweden
| | - J Lindberg
- 1 Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden
| | - J Rutegård
- 1 Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden
| |
Collapse
|
14
|
Lin L, Huang S, Kang M, Ainsley C, Hiltunen P, Vanderstraeten R, Lindberg J, Siljamaki S, Wareing T, Davis I, Barnett A, McGhee J, Solberg T, McDonough J, Simone C. SU-F-T-153: Experimental Validation and Calculation Benchmark for a Commercial Monte Carlo Pencil Beam Scanning Proton Therapy Treatment Planning System in Water. Med Phys 2016. [DOI: 10.1118/1.4956289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
15
|
Ross-Adams H, Lamb A, Dunning M, Halim S, Lindberg J, Massie C, Egevad L, Russell R, Ramos-Montoya A, Vowler S, Sharma N, Kay J, Whitaker H, Clark J, Hurst R, Gnanapragasam V, Shah N, Warren A, Cooper C, Lynch A, Stark R, Mills I, Grönberg H, Neal D. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study. EBioMedicine 2015; 2:1133-44. [PMID: 26501111 PMCID: PMC4588396 DOI: 10.1016/j.ebiom.2015.07.017] [Citation(s) in RCA: 200] [Impact Index Per Article: 22.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2015] [Revised: 07/10/2015] [Accepted: 07/14/2015] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Understanding the heterogeneous genotypes and phenotypes of prostate cancer is fundamental to improving the way we treat this disease. As yet, there are no validated descriptions of prostate cancer subgroups derived from integrated genomics linked with clinical outcome. METHODS In a study of 482 tumour, benign and germline samples from 259 men with primary prostate cancer, we used integrative analysis of copy number alterations (CNA) and array transcriptomics to identify genomic loci that affect expression levels of mRNA in an expression quantitative trait loci (eQTL) approach, to stratify patients into subgroups that we then associated with future clinical behaviour, and compared with either CNA or transcriptomics alone. FINDINGS We identified five separate patient subgroups with distinct genomic alterations and expression profiles based on 100 discriminating genes in our separate discovery and validation sets of 125 and 103 men. These subgroups were able to consistently predict biochemical relapse (p = 0.0017 and p = 0.016 respectively) and were further validated in a third cohort with long-term follow-up (p = 0.027). We show the relative contributions of gene expression and copy number data on phenotype, and demonstrate the improved power gained from integrative analyses. We confirm alterations in six genes previously associated with prostate cancer (MAP3K7, MELK, RCBTB2, ELAC2, TPD52, ZBTB4), and also identify 94 genes not previously linked to prostate cancer progression that would not have been detected using either transcript or copy number data alone. We confirm a number of previously published molecular changes associated with high risk disease, including MYC amplification, and NKX3-1, RB1 and PTEN deletions, as well as over-expression of PCA3 and AMACR, and loss of MSMB in tumour tissue. A subset of the 100 genes outperforms established clinical predictors of poor prognosis (PSA, Gleason score), as well as previously published gene signatures (p = 0.0001). We further show how our molecular profiles can be used for the early detection of aggressive cases in a clinical setting, and inform treatment decisions. INTERPRETATION For the first time in prostate cancer this study demonstrates the importance of integrated genomic analyses incorporating both benign and tumour tissue data in identifying molecular alterations leading to the generation of robust gene sets that are predictive of clinical outcome in independent patient cohorts.
Collapse
Affiliation(s)
- H. Ross-Adams
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK
| | - A.D. Lamb
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK
- Department of Urology, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK
- Academic Urology Group, University of Cambridge, Cambridge, CB2 0QQ, UK
| | - M.J. Dunning
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK
| | - S. Halim
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK
| | - J. Lindberg
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - C.M. Massie
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK
| | - L.A. Egevad
- Department of Oncology–Pathology, Karolinska Institutet, Stockholm, Sweden
| | - R. Russell
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK
| | - A. Ramos-Montoya
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK
| | - S.L. Vowler
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK
| | - N.L. Sharma
- Nuffield Department of Surgical Sciences, University of Oxford, Roosevelt Drive, Oxford, UK
| | - J. Kay
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK
- Molecular Diagnostics and Therapeutics Group, University College London, WC1E 6BT, UK
| | - H. Whitaker
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK
- Molecular Diagnostics and Therapeutics Group, University College London, WC1E 6BT, UK
| | - J. Clark
- University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK
| | - R. Hurst
- University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK
| | - V.J. Gnanapragasam
- Department of Urology, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK
- Academic Urology Group, University of Cambridge, Cambridge, CB2 0QQ, UK
| | - N.C. Shah
- Department of Urology, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK
| | - A.Y. Warren
- Department of Pathology, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK
| | - C.S. Cooper
- University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK
| | - A.G. Lynch
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK
| | - R. Stark
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK
| | - I.G. Mills
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK
- Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, N-0318 Oslo, Norway
- Department of Molecular Oncology, Institute of Cancer Research, Oslo University Hospitals, N-0424 Oslo, Norway
- Prostate Cancer UK/Movember Centre of Excellence for Prostate Cancer Research, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, UK
| | - H. Grönberg
- Academic Urology Group, University of Cambridge, Cambridge, CB2 0QQ, UK
| | - D.E. Neal
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK
- Department of Urology, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK
| | | |
Collapse
|
16
|
Kolmert J, Forngren B, Lindberg J, Öhd J, Åberg KM, Nilsson G, Moritz T, Nordström A. A quantitative LC/MS method targeting urinary 1-methyl-4-imidazoleacetic acid for safety monitoring of the global histamine turnover in clinical studies. Anal Bioanal Chem 2014; 406:1751-62. [PMID: 24429974 DOI: 10.1007/s00216-013-7594-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2013] [Revised: 12/09/2013] [Accepted: 12/19/2013] [Indexed: 11/25/2022]
Abstract
Anaphylaxis is a potentially life-threatening condition triggered mainly by the release of inflammatory mediators, notably histamine. In pharmaceutical research, drug discovery, and clinical evaluation, it may be necessary to accurately assess the potential of a compound, event, or disorder to promote the release of histamine. In contrast to the measurement of plasma histamine, determination of the stable metabolite 1-methyl-4-imidazoleacetic acid (tele-MIAA) in urine provides a noninvasive and more reliable methodology to monitor histamine release. This study presents a repeatable high-performance liquid chromatography coupled to electrospray mass spectrometry (LC-ESI-MS) method where tele-MIAA is baseline separated from its structural isomer 1-methyl-5-imidazoleacetic acid (pi-MIAA) and an unknown in human urine. The ion-pairing chromatography method, in reversed-phase mode, based on 0.5 mM tridecafluoroheptanoic acid demonstrated high repeatability and was applied in a clinical development program that comprised a large number of clinical samples from different cohorts. The inter- and intra-run precision of the method for tele-MIAA were 8.4 and 4.3%, respectively, at the mean urinary concentration level, while method accuracy was between -16.2 and 8.0% across the linear concentration range of 22-1,111 ng mL(-1). Overall, method precision was greater than that reported in previously published methods and enabled the identification of gender differences that were independent of age or demography. The median concentration measured in female subjects was 3.0 μmol mmol(-1) of creatinine, and for male subjects, it was 2.1 μmol mmol(-1) of creatinine. The results demonstrate that the method provides unprecedented accuracy, precision, and practicality for the measurement of tele-MIAA in large clinical settings.
Collapse
Affiliation(s)
- J Kolmert
- Department of Molecular Biology, Umeå University, 901 87, Umeå, Sweden,
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Komoroske LM, Connon RE, Lindberg J, Cheng BS, Castillo G, Hasenbein M, Fangue NA. Ontogeny influences sensitivity to climate change stressors in an endangered fish. Conserv Physiol 2014; 2:cou008. [PMID: 27293629 PMCID: PMC4806739 DOI: 10.1093/conphys/cou008] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/17/2013] [Revised: 01/17/2014] [Accepted: 01/20/2014] [Indexed: 05/20/2023]
Abstract
Coastal ecosystems are among the most human-impacted habitats globally, and their management is often critically linked to recovery of declining native species. In the San Francisco Estuary, the Delta Smelt (Hypomesus transpacificus) is an endemic, endangered fish strongly tied to Californian conservation planning. The complex life history of Delta Smelt combined with dynamic seasonal and spatial abiotic conditions result in dissimilar environments experienced among ontogenetic stages, which may yield stage-specific susceptibility to abiotic stressors. Climate change is forecasted to increase San Francisco Estuary water temperature and salinity; therefore, understanding the influences of ontogeny and phenotypic plasticity on tolerance to these critical environmental parameters is particularly important for Delta Smelt and other San Francisco Estuary fishes. We assessed thermal and salinity limits in several ontogenetic stages and acclimation states of Delta Smelt, and paired these data with environmental data to evaluate sensitivity to climate-change stressors. Thermal tolerance decreased among successive stages, with larval fish exhibiting the highest tolerance and post-spawning adults having the lowest. Delta Smelt had limited capacity to increase tolerance through thermal acclimation, and comparisons with field temperature data revealed that juvenile tolerance limits are the closest to current environmental conditions, which may make this stage especially susceptible to future climate warming. Maximal water temperatures observed in situ exceeded tolerance limits of juveniles and adults. Although these temperature events are currently rare, if they increase in frequency as predicted, it could result in habitat loss at these locations despite other favourable conditions for Delta Smelt. In contrast, Delta Smelt tolerated salinities spanning the range of expected environmental conditions for each ontogenetic stage, but salinity did impact survival in juvenile and adult stages in exposures over acute time scales. Our results underscore the importance of considering ontogeny and phenotypic plasticity in assessing the impacts of climate change, particularly for species adapted to spatially and temporally heterogeneous environments.
Collapse
Affiliation(s)
- L. M. Komoroske
- Department of Wildlife, Fish & Conservation Biology, University of California, Davis, Davis, CA 95616, USA
| | - R. E. Connon
- Department of Anatomy, Physiology and Cell Biology, School of Veterinary Medicine, University of California, Davis, Davis, CA 95616, USA
| | - J. Lindberg
- Fish Conservation and Culture Facility, University of California, Davis, Davis, CA 95616, USA
| | - B. S. Cheng
- Department of Environmental Science and Policy, University of California, Davis, Davis, CA 95616, USA
| | - G. Castillo
- United States Fish and Wildlife Service, Lodi, CA 95240, USA
| | - M. Hasenbein
- Department of Anatomy, Physiology and Cell Biology, School of Veterinary Medicine, University of California, Davis, Davis, CA 95616, USA
- Aquatic Systems Biology Unit, Department of Ecology and Ecosystem Management, Technische Universität München, Muehlenweg 22, D-85354 Freising, Germany
| | - N. A. Fangue
- Department of Wildlife, Fish & Conservation Biology, University of California, Davis, Davis, CA 95616, USA
- Corresponding author: Department of Wildlife, Fish & Conservation Biology, One Shields Avenue, University of California, Davis, Davis, CA 95616, USA. Tel: +1 530 752 6586.
| |
Collapse
|
18
|
Lindberg J, Kreuter M, Person LO, Taft C. Patient Participation in Rehabilitation Questionnaire (PPRQ)-development and psychometric evaluation. Spinal Cord 2013; 51:838-42. [PMID: 24042990 DOI: 10.1038/sc.2013.98] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2013] [Revised: 08/01/2013] [Accepted: 08/02/2013] [Indexed: 11/09/2022]
Abstract
STUDY DESIGN A cross-sectional postal questionnaire study. OBJECTIVES The aim of the study was to evaluate selected psychometric properties of a draft version of the Patient Participation in Rehabilitation Questionnaire (PPRQ) measuring patients' experiences of participation in care and rehabilitation. SETTING Sweden. METHODS On the basis of previous qualitative analyses of patient interview data, a 32-item questionnaire covering five domains of participation was developed and sent to 268 persons with spinal cord injury, aged 18-80 years and injured 1-12 years previously. In total, 141 (51%) evaluable questionnaires were returned. Multi-trait analysis was used to assess scaling assumptions by testing item convergent and discriminant validity and internal consistency reliability (Cronbach's α) associated with the hypothesized item-scale structure of the questionnaire. RESULT Nine items failed to meet scaling assumptions and were omitted. Scaling assumptions were thereafter substantiated for the scales: 'respect and integrity' (6 items); 'planning and decision-making' (4 items); 'information and knowledge' (4 items); 'motivation and encouragement' (5 items); and 'involvement of family' (4 items). Item-scale correlations ranged from 0.67 to 0.85 and most items correlated higher or significantly higher with their hypothesized scale than with other scales. Cronbach's α was 0.89 for all scales. CONCLUSION The PPRQ appears to adequately assess central aspects of participation in care and rehabilitation from the perspective of patients with spinal cord injury. Further studies using larger samples will be undertaken to confirm the scale structure as well as the sensitivity and responsiveness of the questionnaire.
Collapse
Affiliation(s)
- J Lindberg
- 1] Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden [2] Gothenburg Centre for Person-Centred Care (GPCC), University of Gothenburg, Gothenburg, Sweden
| | | | | | | |
Collapse
|
19
|
Lindberg J, Kreuter M, Taft C, Person LO. Patient participation in care and rehabilitation from the perspective of patients with spinal cord injury. Spinal Cord 2013; 51:834-7. [PMID: 23999110 DOI: 10.1038/sc.2013.97] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2013] [Revised: 07/09/2013] [Accepted: 07/09/2013] [Indexed: 11/09/2022]
Abstract
STUDY DESIGN Qualitative method, semi-structured interviews. OBJECTIVES The aim of the study was to explore the meaning of patient participation in care and rehabilitation from the perspective of patients with spinal cord injury (SCI). SETTING Post discharge community setting. METHODS Semi-structured interviews were performed with 10 persons with SCI representing different ages, gender and levels of injury. All interviews were conducted individually and lasted 40-120 min. The interviews were verbally transcribed and the data were analyzed by means of content analysis. RESULTS All informants stressed the importance of patient participation as a necessary prerequisite for successful care and rehabilitation, but emphasized that participation must be tailored to each patient's own preferences, capacities and needs. They also underscored that the staff should be sensitive and responsive to the fact that desired levels and kinds of participation may vary from patient to patient, as well as for the same patient during the course of the rehabilitation. Five themes reflecting central aspects of participation emerged: respect and integrity, planning and decision-making, information and knowledge, motivation and encouragement, and involvement of family. CONCLUSIONS Patient participation is a critical component of successful SCI rehabilitation and must be facilitated, promoted and tailored to each patient by the staff. Based on the finding from this study a questionnaire has been developed for assessing patient experiences of five domains of participation in rehabilitation to serve as a tool to help in evaluating provided care and in identifying patients' preferences for participation.
Collapse
Affiliation(s)
- J Lindberg
- 1] Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden [2] Gothenburg Centre for Person-Centred Care (GPCC), University of Gothenburg, Gothenburg, Sweden
| | | | | | | |
Collapse
|
20
|
Falkenius J, Lindberg J, Johansson H, Frostvik-Stolt M, Lundeberg J, Hansson J, Egyhazi S. A gene expression profile associated with clinical outcome in stage III melanoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8551] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Thi Thuy N, Lindberg J, Ogle B. Effects of replacing fish meal with ensiled catfish ( Pangasius hypophthalmus) by-products on the performance and carcass quality of finishing pigs. J Anim Feed Sci 2011. [DOI: 10.22358/jafs/66157/2011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
22
|
|
23
|
Lindberg J. Rupture of the right ventricle of the heart in a case of advanced heart amyloidosis. Acta Pathol Microbiol Scand A 2009; 79:53-4. [PMID: 4100598 DOI: 10.1111/j.1699-0463.1971.tb00513.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
24
|
|
25
|
Ka S, Lindberg J, Strömstedt L, Fitzsimmons C, Lindqvist N, Lundeberg J, Siegel PB, Andersson L, Hallböök F. Extremely different behaviours in high and low body weight lines of chicken are associated with differential expression of genes involved in neuronal plasticity. J Neuroendocrinol 2009; 21:208-16. [PMID: 19207828 DOI: 10.1111/j.1365-2826.2009.01819.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Long-term selection (> 45 generations) for low or high body weight from the same founder population has generated two extremely divergent lines of chickens, the low (LWS) and high weight (HWS) lines, which at the age of selection (56 days) differs by more than nine-fold in body weight. The HWS line chickens are compulsive feeders, whereas, in the LWS line, some individuals are anorexic and others have very low appetites. The involvement of the central nervous system in these behavioural differences has been experimentally supported. We compared a brain region at 0 and 56 days of age containing the major metabolic regulatory regions, including the hypothalamus and brainstem, using a global cDNA array expression analysis. The results obtained show that the long-term selection has produced minor but multiple expression differences. Genes that regulate neuronal plasticity, such as actin filament polymerisation and brain-derived neurotrophic factor, were identified as being differentially expressed. Genes involved in lipid metabolism were over-represented among differentially expressed genes. The expression data confirm that neural systems regulating feeding behaviours in these lines are different. The results suggest that the lines are set in separate developmental trajectories equipped with slightly different nervous systems. We suggest that the lines adapt behaviourally different to changing situations post hatch, such as the transition from dependence on yolk to feeding, in order to obtain energy. The present study has identified and exemplifies the kind of changes that may underlie the extreme differences in such behaviours.
Collapse
Affiliation(s)
- S Ka
- Department of Neuroscience, Uppsala University, Uppsala, Sweden
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Snir O, Widhe M, von Spee C, Lindberg J, Padyukov L, Lundberg K, Engström A, Venables PJ, Lundeberg J, Holmdahl R, Klareskog L, Malmström V. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann Rheum Dis 2008; 68:736-43. [PMID: 18635594 DOI: 10.1136/ard.2008.091355] [Citation(s) in RCA: 145] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BACKGROUND Autoantibodies to cyclic citrullinated peptides (anti-CCP) are present in most patients with rheumatoid arthritis (RA), and associate with HLA-DRB1 shared epitope (SE) alleles. OBJECTIVE To investigate reactivities of anti-CCP to various citrullinated proteins/peptides, which represent potential autoantigens in RA, and to examine the relationship between such antibodies, and their association with genetic variants within HLA-DRB1 SE alleles. METHODS Serum samples from 291 patients with established RA and 100 sex- and age-matched healthy subjects were included in this study. Sera were first analysed for presence of anti-CCP antibodies and further for IgG and IgA antibodies towards candidate autoantigens in both their native and citrullinated form including: fibrinogen, alpha-enolase peptide-1 and the C1-epitope of type II collagen (C1(III)). Antibody specificity was confirmed by cross-reactivity tests. HLA-DR genotyping was performed. RESULTS 72% of patients with RA were anti-CCP positive. Among the candidate autoantigens examined, IgG antibodies to citrullinated fibrinogen were found in 66% of patients' sera and in 41% for both citrullinated alpha-enolase peptide-1 and citrullinated C1(III). These antibodies were mainly seen in the anti-CCP-positive patient group; they were specific for their respective antigen and displayed limited cross reactivity. IgA responses were also detected, but less frequently than IgG. Anti-CCP and anti-citrullinated protein antibodies were associated with HLA-DRB1*04 rather than with HLA-DRB1*01 alleles. CONCLUSIONS Antibodies directed against several citrullinated antigens are present in CCP-positive RA, with many patients displaying multireactivity. All specific reactivities were primarily associated with the HLA-DRB1*04 alleles, suggesting common pathways of anti-citrulline immunity.
Collapse
Affiliation(s)
- O Snir
- Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institute, Solna, Stockholm, Sweden
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Lindberg J, Lindfors K, Setälä T, Kaivola M. Dipole-dipole interaction between molecules mediated by a chain of silver nanoparticles. J Opt Soc Am A Opt Image Sci Vis 2007; 24:3427-3431. [PMID: 17975568 DOI: 10.1364/josaa.24.003427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
We study the dipole-dipole coupling between two fluorescent molecules in the presence of a chain of metallic nanoparticles. We analyze the spectral behavior of the coupling strength and its dependence on the molecular orientation. Our results show that for certain resonant wavelengths the coupling strength between the molecules is greatly enhanced and is strongly polarization sensitive. We also demonstrate how metallic nanoparticles can be utilized in implementing a polarization-sensitive coupler.
Collapse
Affiliation(s)
- J Lindberg
- Department of Engineering Physics and Mathematics and Center for New Materials, Helsinki University ofTechnology (TKK), PO Box 3500, FI-02015 TKK, Finland.
| | | | | | | |
Collapse
|
28
|
Lindberg J, Stenling R, Palmqvist R, Rutegård J. Surgery for neoplastic changes in ulcerative colitis--can limited resection be justified? Outcome for patients who underwent limited surgery. Colorectal Dis 2006; 8:551-6. [PMID: 16919105 DOI: 10.1111/j.1463-1318.2006.00997.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
BACKGROUND Patients with ulcerative colitis (UC) are at an increased risk of developing colorectal cancer (CRC). The aim of this study was to investigate the outcome for the patients who underwent limited resection of the colon and/or rectum instead of panproctocolectomy (PPC), with special attention to those with neoplastic changes. METHODS Since 1977, all known patients with UC from our catchment area have been included in our surveillance programme. A total of 210 patients with UC have been followed up with regular colonoscopies and biopsies. Indications for surgery were severe therapy-resistant disease (TRD), high-grade dysplasia (HGD), CRC or repeated findings of low-grade dysplasia (LGD). Patient compliance was excellent. RESULTS Fifty-one patients were operated on. In 29 of these patients, PPC was performed initially. At the end-point of the study, additionally seven patients had been radically operated on and three more patients planned to undergo such an operation. Accordingly, 22 patients had their first operation performed as a resection of either a part of or the whole colon or rectum. In this group, there were four patients diagnosed with CRC and three with dysplasia-associated lesion or mass (DALM). One of them died 6 months after surgery because of disseminated CRC, whereas the other patients were alive at the end-point of the study. One of these seven patients with CRC or DALM had at end-point been radically operated on and two patients were awaiting such a procedure (in two patients because of LGD and in one patient because of TRD). Six of the patients who had a colorectal resection performed on the indication of TRD were radically operated later on, five of them because of relapsed TRD and one patient because of LGD in the remaining rectal mucosa. Twenty-one patients gained a mean of 9.4 years with presumably better bowel function, from undergoing a limited resection instead of PPC. None of the patients who underwent a colonic and/or rectal resection died because of CRC or metachronous cancer in their remaining colon or rectum. CONCLUSION The results of this study indicate that a limited resection of the colon and/or rectum in patients with UC, which requires surgical intervention increases the time with presumably better bowel function and may therefore be an alternative to PPC without increased risk of dying from CRC. This is dependent on the flexibility of the medical service and patient compliance.
Collapse
Affiliation(s)
- J Lindberg
- Department of Surgery, Ornsköldsvik Hospital, Ornsköldsvik, Sweden.
| | | | | | | |
Collapse
|
29
|
Hautakorpi M, Lindberg J, Setälä T, Kaivola M. Rotational frequency shifts in partially coherent optical fields. J Opt Soc Am A Opt Image Sci Vis 2006; 23:1159-63. [PMID: 16642194 DOI: 10.1364/josaa.23.001159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
We study the frequency shifts taking place when a random, stationary optical field rotates with respect to an observer. The field is expanded in terms of fully coherent Laguerre-Gaussian basis modes, for which the rotational frequency shifts have been studied previously. We demonstrate the formalism by considering the spectrum of a Gaussian Schell-model field, and show that for a spatially highly incoherent field, significant spectral changes can be expected.
Collapse
Affiliation(s)
- M Hautakorpi
- Optics and Molecular Materials, Helsinki University of Technology, Finland.
| | | | | | | |
Collapse
|
30
|
Smith L, Lindberg J. Über die Genauigkeit und die praktische Ausführung der quantitativen kinetischen Analyse bei bimolekularen Reaktionen. ACTA ACUST UNITED AC 2006. [DOI: 10.1002/cber.19280610824] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
31
|
Torgrip RJO, Lindberg J, Linder M, Karlberg B, Jacobsson SP, Kolmert J, Gustafsson I, Schuppe-Koistinen I. New modes of data partitioning based on PARS peak alignment for improved multivariate biomarker/biopattern detection in 1H-NMR spectroscopic metabolic profiling of urine. Metabolomics 2006; 2:1-19. [PMID: 24489529 PMCID: PMC3906737 DOI: 10.1007/s11306-005-0013-z] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/02/2005] [Accepted: 10/03/2005] [Indexed: 11/30/2022]
Abstract
This paper addresses the possibility of mathematically partition and process urine 1H-NMR spectra to enhance the efficiency of the subsequent multivariate data analysis in the context of metabolic profiling of a toxicity study. We show that by processing the NMR data with the peak alignment using reduced set mapping (PARS) algorithm and the use of sparse representation of the data results in the information contained in the original NMR data being preserved with retained resolution but free of the problem of peak shifts. We can now describe a method for differential expression analysis of NMR spectra by using prior knowledge, i.e., the onset of dosing, a partitioning not possible to achieve using raw or bucketed data. In addition we also outline a scheme for soft removal of "biological noise" from the aligned data: exhaustive bio-noise subtraction (EBS). The result is a straightforward protocol for detection of peaks that appear as a consequence of the drug response. In other words, it is possible to elucidate peak origin, either from endogenous substances or from the administered drug/biomarkers. The partition of data originating from the normally regulating metabolome can, furthermore, be analyzed free of the superimposed biological noise. The proposed protocol results in enhanced interpretability of the processed data, i.e., a more refined metabolic trace, simplification of detection of consistent biomarkers, and a simplified search for metabolic end products of the administered drug.
Collapse
Affiliation(s)
- R. J. O. Torgrip
- Department of Analytical Chemistry, BioSysteMetrics Group, Stockholm University, SE-106 91 Stockholm, Sweden
- Safety Assessment, Molecular Toxicology, AstraZeneca R&D Södertälje, SE-151 85 Södertälje, Sweden
| | - J. Lindberg
- Safety Assessment, Molecular Toxicology, AstraZeneca R&D Södertälje, SE-151 85 Södertälje, Sweden
| | - M. Linder
- Statistical Science, AstraZeneca R&D Södertälje, SE-151 85 Södertälje, Sweden
| | - B. Karlberg
- Department of Analytical Chemistry, BioSysteMetrics Group, Stockholm University, SE-106 91 Stockholm, Sweden
| | - S. P. Jacobsson
- Department of Analytical Chemistry, BioSysteMetrics Group, Stockholm University, SE-106 91 Stockholm, Sweden
- PAR&D, AstraZeneca R&D Södertälje, SE-151 85 Södertälje, Sweden
| | - J. Kolmert
- Safety Assessment, Molecular Toxicology, AstraZeneca R&D Södertälje, SE-151 85 Södertälje, Sweden
| | - I. Gustafsson
- Safety Assessment, Molecular Toxicology, AstraZeneca R&D Södertälje, SE-151 85 Södertälje, Sweden
| | - I. Schuppe-Koistinen
- Safety Assessment, Molecular Toxicology, AstraZeneca R&D Södertälje, SE-151 85 Södertälje, Sweden
| |
Collapse
|
32
|
|
33
|
Lindberg J, af Klint E, Stark A, Andersson T, Nilsson P, Klareskog L, Ulfgren A, Lundeberg J. Arthritis Res Ther 2005; 7:P116. [DOI: 10.1186/ar1637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
34
|
|
35
|
Gil JP, Nogueira F, Strömberg-Nörklit J, Lindberg J, Carrolo M, Casimiro C, Lopes D, Arez AP, Cravo PV, Rosário VE. Detection of atovaquone and Malarone resistance conferring mutations in Plasmodium falciparum cytochrome b gene (cytb). Mol Cell Probes 2003; 17:85-9. [PMID: 12788029 DOI: 10.1016/s0890-8508(03)00006-9] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Clinical treatment failures of the hydroxynaphthoquinone atovaquone or its combination with proguanil (Malarone) in Plasmodium falciparum malaria has been recently documented. These events have been associated to single nucleotide polymorphisms (SNPs) in the parasite cytochrome b gene (cytb). In this report we describe a set of nest PCR-RFLP methods developed for the fast detection of all known cytb mutations associated to resistance to these drugs. The methods were successfully applied for the analysis of phenol-chloroform extracted DNA samples from patients not cured by Malarone, and from an established parasite clone. Further, the protocol for the detection of the A803C mutation was applied to 164 DNA field samples extracted through crude methanol-based protocols, originated from several malaria settings. The PCR-RFLP methods here presented can be used as a valuable for the clinical detection and study of Malarone and atovaquone P. falciparum resistance.
Collapse
Affiliation(s)
- J P Gil
- UEI Malária, Centro de Malária e outras Doenças Tropicais, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisboa, Portugal.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Påhlsson P, Spitalnik SL, Spitalnik PF, Fantini J, Rakotonirainy O, Ghardashkhani S, Lindberg J, Konradsson P, Larson G. Characterization of galactosyl glycerolipids in the HT29 human colon carcinoma cell line. Arch Biochem Biophys 2001; 396:187-98. [PMID: 11747296 DOI: 10.1006/abbi.2001.2610] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Glycoglycerolipids constitute a family of glycolipids with apparently very restricted expression in human tissues. They have previously been detected only in the testis and the nervous system. In the present study, two glycoglycerolipids were isolated from the HT29 human colon carcinoma cell line. The glycoglycerolipids were structurally characterized as a monogalactosylglycerolipid (1-O-alkyl-2-O-acyl-3-O-(beta-galactosyl)-sn-glycerol) and a digalactosylglycerolipid (1-O-alkyl-2-O-acyl-3-O-(beta-galactosyl(1-4)alpha-galactosyl)-sn-glycerol) using NMR and mass spectrometry. This digalactosylglycerolipid has not previously been structurally characterized. When HT29 cells were allowed to differentiate into more enterocyte-like cells by culture in glucose-free medium, expression of both of these glycoglycerolipids was greatly diminished. The presence of glycoglycerolipids in a human colon carcinoma cell line indicates that expression of this family of glycolipids may not be as restricted as previously thought. Instead this class of glycolipids may serve as differentiation antigens in various normal tissues and in tumor development. The Galalpha1-4Gal epitope was previously identified as a receptor for bacterial adhesins and toxins. The finding that this epitope is also linked to a glycerolipid moiety opens up new possible roles for this carbohydrate receptor in intracellular signaling.
Collapse
Affiliation(s)
- P Påhlsson
- Department of Biomedicine and Surgery, Linköping University, S-581 85 Linköping, Sweden.
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Mühlman A, Lindberg J, Classon B, Unge T, Hallberg A, Samuelsson B. Synthesis of novel, potent, diol-based HIV-1 protease inhibitors via intermolecular pinacol homocoupling of (2S)-2-benzyloxymethyl-4-phenylbutanal. J Med Chem 2001; 44:3407-16. [PMID: 11585446 DOI: 10.1021/jm0011171] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The synthesis of novel, potent, diol-based HIV-1 protease inhibitors, having phenethyl groups (-CH(2)CH(2)Ph) in P1/P1' position is described. An intermolecular pinacol homocoupling of (2S)-2-benzyloxymethyl-4-phenylbutanal 16 was the key step in the synthesis. From this reaction sequence four carba analogues, compounds 8a, 8b, 9a, and 9b, were prepared, having the inverted configuration of one or both of the stereogenic centers carrying the diol hydroxyls as compared to the parent series represented by inhibitors 6 and 7. Inhibitor 8b was found to be a potent inhibitor of HIV-1 protease (PR), showing excellent antiviral activity in the cell-based assay and in the presence of 40% human serum. The absolute stereochemistry of the central diol of the potent inhibitor (8b) was determined from the X-ray crystallographic structure of its complex with HIV-1 PR.
Collapse
Affiliation(s)
- A Mühlman
- Department of Organic Chemistry, Arrhenius Laboratory, Stockholm University, SE-106 91 Stockholm, Sweden
| | | | | | | | | | | |
Collapse
|
38
|
Lindberg J, Martin KJ, González EA, Acchiardo SR, Valdin JR, Soltanek C. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 2001; 56:315-23. [PMID: 11680662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023] Open
Abstract
BACKGROUND Paricalcitol is a vitamin D analog approved for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. This study was designed to evaluate the long-term efficacy and safety of paricalcitol. Additional analysis evaluated the effects of paricalcitol in hypocalcemic and hyperphosphatemic subpopulations. PATIENTS AND METHODS One hundred sixty-four end-stage renal disease (ESRD) patiesnts on hemodialysis were treated in an open-label, multicenter study lasting up to 13 months in duration. After a baseline or washout period, an initial starting dose of 0.04-0.393 microg/kg was given 2-3 times per week. This dose was adjusted at the discretion of the investigator according to the patient's intact parathyroid hormone level (iPTH), calcium level, and calcium-phosphorus (Ca x P) product. The therapy was intended to reproduce expected clinical use of paricalcitol. Patients represented a wide cross-section of the ESRD population, and were not excluded from the study based on age or underlying disease. RESULTS The mean paricalcitol dose level throughout the study was 0.10 microg/kg. The mean iPTH levels (baseline mean 628.3 +/- 27.65 pg/ml) decreased rapidly during the first 4 months of therapy, and reached the designated target range (100-300 pg/ml) by month 5 (mean 295.3 +/- 25.69 pg/ml). A maximum mean decrease in iPTH level of 409 +/- 35.01 pg/ml was seen at month 13. Throughout the course of the study, the mean normalized calcium level was maintained well within the normal range (9.44-9.94 mg/dl). The mean phosphorus level was maintained in an acceptable range throughout the study (5.92-6.53 mg/dl). Mean Ca x P product was maintained between 52 and 65. Mean alkaline phosphatase levels decreased significantly from baseline with a maximum mean decrease of 62 +/- 17.3 U/l observed at month 9. In 34 initially hypocalcemic patients (mean of 7.7 mg/dl) iPTH levels decreased from baseline, on average, by 443 +/- 81.86 pg/ml while mean calcium levels rose by 1.2 +/- 0.23 mg/dl to reach the normal range. In 35 initially hyperphosphatemic patients (mean of 8.0 mg/dl) iPTH levels decreased, on average, by 515 +/- 103.31 pg/ml with an associated mean decrease in phosphorus of 0.57 +/- 0.52 mg/dl. Adverse events that were considered by the investigator to have a possible. probable, or definite relationship to study drug occurred in 26% of patients. Other than expected temporary effects of hypercalcemia and hyperphosphatemia. the only possible trends for causally-related adverse events were for nausea/vomiting and metallic taste. CONCLUSIONS This long-term study of paricalcitol demonstrates that it rapidly and effectively suppresses iPTH levels in a wide spectrum of ESRD patients and caused no unexpected adverse events.
Collapse
Affiliation(s)
- J Lindberg
- Ochsner Clinic-New Orleans Chronic Hemodialysis Unit, LA 70121, USA.
| | | | | | | | | | | |
Collapse
|
39
|
Pyring D, Lindberg J, Zuccarello G, Kvarnström I, Zhang H, Vrang L, Unge T, Classon B, Hallberg A, Samuelsson B. Design and synthesis of potent C(2)-symmetric diol-based HIV-1 protease inhibitors: effects of fluoro substitution. J Med Chem 2001; 44:3083-91. [PMID: 11543677 DOI: 10.1021/jm001134q] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Implementation of derivatized carbohydrates as C(2)-symmetric HIV-1 protease inhibitors has previously been reported. With the objective of improving the anti-HIV activity of such compounds, we synthesized a series of fluoro substituted P1/P1' analogues. These compounds were evaluated for antiviral activity toward both wild type and mutant virus. The potency of the analogues in blocking HIV-1 protease was moderate, with K(i) values ranging from 1 to 7 nM. Nonetheless, compared to the parent nonfluorous inhibitors, a majority of the compounds exhibited improved antiviral activity, for example the 3-fluorobenzyl derivative 9b, which had a K(i) value of 7.13 nM and displayed one of the most powerful antiviral activities in the cellular assay of the series. Our results strongly suggest that fluoro substitution can substantially improve antiviral activity. The X-ray crystal structures of two of the fluoro substituted inhibitors (9a and 9f) cocrystallized with HIV-1 protease are discussed.
Collapse
Affiliation(s)
- D Pyring
- Department of Chemistry, Linköping University, SE-581 83 Linköping, Sweden
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Lindberg J. Treatment strategies for renal bone disease. Nephrol News Issues 2001; 15:21-4. [PMID: 12099184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
Renal bone disease encompasses a wide range of bone abnormalities that are intricately linked with metabolic systems that are driven by calcium, phosphorus, PTH, and D hormone levels. An integrated approach to treatment must involve both dietary measures, use of phosphate binders as appropriate, and D hormone replacement. Not incidentally, implementation of this integrated approach involves not only our patients but everyone associated in their care, especially the nephrologist, nephrology nurse, and renal dietitians. Improving patient outcomes--preventing or minimizing renal bone disease and the complications of secondary hyperparathyroidism--will require communication and cooperation between all of us on behalf of our patients.
Collapse
|
41
|
Lindberg J, Fernandez MA, Ropp JD, Hamm-Alvarez SF. Nocodazole treatment of CV-1 cells enhances nuclear/perinuclear accumulation of lipid-DNA complexes and increases gene expression. Pharm Res 2001; 18:246-9. [PMID: 11405299 DOI: 10.1023/a:1011001022570] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- J Lindberg
- Department of Pharmaceutical Sciences, University of Southern California, Los Angeles, USA
| | | | | | | |
Collapse
|
42
|
Schaal W, Karlsson A, Ahlsén G, Lindberg J, Andersson HO, Danielson UH, Classon B, Unge T, Samuelsson B, Hultén J, Hallberg A, Karlén A. Synthesis and comparative molecular field analysis (CoMFA) of symmetric and nonsymmetric cyclic sulfamide HIV-1 protease inhibitors. J Med Chem 2001; 44:155-69. [PMID: 11170625 DOI: 10.1021/jm001024j] [Citation(s) in RCA: 89] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
We have previously reported on the unexpected flipped conformation in the cyclic sulfamide class of inhibitors. An attempt to induce a symmetric binding conformation by introducing P2/P2' substituents foreseen to bind preferentially in the S2/S2' subsite was unsuccessful. On the basis of the flipped conformation we anticipated that nonsymmetric sulfamide inhibitors, with P2/P2' side chains modified individually for the S1' and S2 subsites, should be more potent than the corresponding symmetric analogues. To test this hypothesis, a set of 18 cyclic sulfamide inhibitors (11 nonsymmetric and 7 symmetric) with different P2/P2' substituents was prepared and evaluated in an enzyme assay. To rationalize the structure-activity relationship (SAR) and enable the alignment of the nonsymmetric inhibitors, i.e., which of the P2/P2' substituents of the nonsymmetric inhibitors interact with which subsite, a CoMFA study was performed. The CoMFA model, constructed from the 18 inhibitors in this study along with seven inhibitors from previous work by our group, has successfully been used to rationalize the SAR of the cyclic sulfamide inhibitors. Furthermore, from the information presented herein, the SAR of the cyclic sulfamide class of inhibitors seems to differ from the SAR of the related cyclic urea inhibitors reported by DuPont and DuPont-Merck.
Collapse
Affiliation(s)
- W Schaal
- Department of Organic Pharmaceutical Chemistry, Uppsala Biomedical Centre, Uppsala University, Box 574, SE-751 23 Uppsala, Sweden
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Abstract
One of the greatest remaining challenges facing nephrology research is obtaining data with detail and precision for the three large, yet "forgotten," populations that span the spectrum of kidney disease: patients with chronic renal insufficiency (CRI), peritoneal dialysis patients, and kidney transplant patients. Studies of these populations, particularly the CRI group, are hampered by the relative mobility of these patients, the lack of stringent epidemiologic or clinical definitions, and the tendency to extrapolate data from hemodialysis populations into other clinical settings. This article suggests a two-pronged approach to a research agenda: first, by recognizing the need for better data regarding the natural history of these kidney failure subsets and their comorbidities; and second, by directing greater effort at identifying rational, efficacious, and cost-effective interventions to influence their natural history positively. Specific efforts are suggested in all three populations. For patients with CRI, studies should be directed at (1) identifying high-risk patients; (2) determining methods for making optimal referrals to the nephrologist; (3) identifying and managing CRI, its complications, and its comorbid conditions; and (4) establishing processes for the smooth transition to dialysis. The peritoneal dialysis population will benefit from studies addressing the treatment of anemia and its ability to modify cardiovascular illness and quality of life. Kidney transplant studies should also focus on the identification and management of comorbid conditions, as well as the effects of various interventions on quality of life. Rational evidence-based care of these conditions, which are critically important to patients, their families, and the health care system in general, must await the conduct of well-designed prospective observational and interventional trials.
Collapse
Affiliation(s)
- J Lindberg
- Ochsner Clinic, New Orleans, LA 70121, USA.
| | | | | |
Collapse
|
44
|
Lindstedt G, Lundberg PA, Larsson B, Lindberg J, Mattsby-Baltzer I, Lange S. [Increased procalcitonin level in bacteriogenic metabolic disturbances. A new possibility for diagnosis and treatment monitoring in sepsis]. Lakartidningen 2000; 97:3995-6, 3999-4001. [PMID: 11036357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
Earlier observations of increased plasma concentrations of immunoreactive calcitonin (32 amino acids) in sepsis and other non-tumorous conditions may be explained by increased secretion of procalcitonin, the 116-amino acid prohormone. At present, the site(s) of origin of procalcitonin in sepsis, the factors regulating its biosynthesis and release, the route(s) of its elimination from blood as well as its biological function(s) are unknown. The rapid increase in procalcitonin concentration in sepsis--in some patients earlier than that of C-reactive protein--and decrease upon successful chemotherapy makes procalcitonin a potentially important biomarker in monitoring patients with suspected or confirmed sepsis.
Collapse
Affiliation(s)
- G Lindstedt
- Avdelningen för klinisk kemi och transfusionsmedicin, Göteborgs universitet, Sahlgrenska.
| | | | | | | | | | | |
Collapse
|
45
|
Shen Y, Lu Z, Spiers S, MacKenzie HA, Ashton HS, Hannigan J, Freeborn SS, Lindberg J. Measurement of the optical absorption coefficient of a liquid by use of a time-resolved photoacoustic technique. Appl Opt 2000; 39:4007-4012. [PMID: 18349982 DOI: 10.1364/ao.39.004007] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
A time-resolved photoacoustic technique has been applied to the study of dissolved and dispersed absorbers in aqueous systems. The temporal pressure profiles generated from colloidal graphite and glucose solutions were measured, and it was found that the amplitude of the photoacoustic signal of both the glucose and the colloidal graphite solutions increase linearly with concentration and that acoustic signal time delay yields the acoustic velocity. The logarithm of the photoacoustic signal amplitude changes linearly with the time delay, with a slope that is proportional to the product of the acoustic velocity and the optical absorption that can thus be determined.
Collapse
Affiliation(s)
- Y Shen
- National Laboratory of Molecular and Biomolecular Electronics, Southeast University, Nanjing 210096, China.
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Abstract
Pneumococcal endocarditis most often presents as an ulcerative endocarditis causing rapid destruction of the normal aortic valve, leading to aortic insufficiency and acute heart failure. Alcoholism is the most frequent underlying medical condition. This case illustrates that pneumococcal endocarditis can reoccur and is able to attack healthy, as well as previously damaged, heart valves. It also illustrates that vaccination of certain groups should be considered. The importance of repeated heart stethoscopy in patients with pneumococcaemia is emphasized.
Collapse
Affiliation(s)
- J Lindberg
- Department of Clinical Microbiology, Viborg Hospital, Denmark
| | | |
Collapse
|
47
|
Self I, Lindberg J, Filangeri J, Anderson S, Szerlip M, Best J, Sadler R, Savoie J, Jackson D, James C, Husserl F, Copely JB. The healthy start renal clinic: benefits of tracking and early intervention in pre-end stage renal disease patients. Ochsner J 1999; 1:202-205. [PMID: 21845139 PMCID: PMC3145441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023] Open
Abstract
Several studies have demonstrated a strong association between the benefits of pre-end stage renal disease (ESRD) education and decreased length of hospital stay (LOS) and hospital charges, delay of renal replacement therapy (RRT), and a smooth transition to RRT. The Ochsner Healthy Start Renal Clinic (HSRC) is a multidisciplinary early education and tracking program for pre-ESRD patients and their families. We identified and educated pre-ESRD patients about kidney disease, allowing them to discuss and make informed decisions about their treatment and be better prepared to cope with the transition to RRT and the changes in their lives resulting from kidney failure. HSRC patients demonstrated a significant decrease in length of hospital stay (p = 0.05), a trend towards decreased hospital episodes and charges, decreased use of temporary venous access, and a smooth transition to RRT. The control group was made up of patients who had either refused the structured education or had been referred to HSRC late and received only conventional instruction by a social worker at the point where dialysis was imminent. We compared the number of episodes of hospitalization, LOS, and overall hospital charges for the period immediately surrounding initiation of chronic dialysis (2 months before and 1 month following onset) of all 36 patients who began chronic hemodialysis in our facility between November 1997 and November 1998. HSRC patients had LOS half as long (p=0.05), fewer hospital episodes, and hospital charges of $5,000 less per patient than the non-HSRC group. Initial data strongly suggest that early education and intervention through the coordination of a multidisciplinary team maximize the continuity of patient care.
Collapse
Affiliation(s)
- I Self
- Section on Nephrology, Ochsner Clinic and Alton Ochsner Medical Foundation
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
MacKenzie HA, Ashton HS, Spiers S, Shen Y, Freeborn SS, Hannigan J, Lindberg J, Rae P. Advances in photoacoustic noninvasive glucose testing. Clin Chem 1999; 45:1587-95. [PMID: 10471673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
We report here on in vitro and in vivo experiments that are intended to explore the feasibility of photoacoustic spectroscopy as a tool for the noninvasive measurement of blood glucose. The in vivo results from oral glucose tests on eight subjects showed good correlation with clinical measurements but indicated that physiological factors and person-to-person variability are important. In vitro measurements showed that the sensitivity of the glucose measurement is unaffected by the presence of common blood analytes but that there can be substantial shifts in baseline values. The results indicate the need for spectroscopic data to develop algorithms for the detection of glucose in the presence of other analytes.
Collapse
Affiliation(s)
- H A MacKenzie
- Department of Physics, Heriot-Watt University, Riccarton, Edinburgh EH14 4AS, Scotland.
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Söderström A, Lindh M, Eriksson K, Horal P, Krantz M, Kristiansson B, Lindberg J, Norkrans G. Chronic hepatitis B in children in Gothenburg, Sweden. Scand J Infect Dis 1999; 31:109-14. [PMID: 10447315 DOI: 10.1080/003655499750006100] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Sweden is a low prevalence area for hepatitis B, but the number of chronic carriers has increased during the last decade due to immigration. Out of a total of 120 children with identified chronic hepatitis B in Gothenburg, Sweden, 93 were investigated during the 2-year period 1994-95. The children had a mean age of 10.9 years and originated from 21 different countries. Most infections were discovered during various screening programmes after arrival in Sweden. A total of 90 of the 93 children were HBV-DNA positive by Amplicor HBV Monitor (Roche Diagnostics) and 58% (54/93) were HBeAg positive. All children either originated from areas with a high or medium prevalence of HBV infection (81/93, 87%) or were born in Sweden to mothers originating from high or medium prevalence countries (12/93, 13%). Three of these 12 children were vertically infected in spite of adequate immunoprophylaxis and 8 were born to mothers with undiscovered chronic HBV infection. In all, 34 children had mothers who were HBsAg positive. No overt case of transmission was notified in day-care centres or schools, or from a child to a non-immune parent. None of the children reported any symptoms of liver disease, but 38% (35/93) had elevated aminotransferases. Therefore, screening programmes are essential to identify chronic HBV infection in children in order to prevent transmission and to find individuals at risk of progressive liver damage who should be considered for treatment.
Collapse
Affiliation(s)
- A Söderström
- Department of Infectious Diseases, Sahlgrenska University Hospital, Ostra, Göteborg, Sweden
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Lindberg J, Martín-Fontecha A, Höglund P. Natural killing of MHC class I(-) lymphoblasts by NK cells from long-term bone marrow culture requires effector cell expression of Ly49 receptors. Int Immunol 1999; 11:1239-46. [PMID: 10421781 DOI: 10.1093/intimm/11.8.1239] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
NK cells from long-term bone marrow culture (LTBMC) were compared with IL-2-activated splenic NK cells [short-term spleen cell culture (STSC)] with regard to expression of inhibitory Ly49 receptors and cytotoxic function. In the LTBMC, the total number of NK cells expressing either one of the Ly49 molecules A, C/I and G2 was strongly reduced (10-15% of NK1.1(+) cells) compared to the STSC (80-90% of NK1.1(+) cells). With regard to cytotoxic function, we confirmed that LTBMC-derived NK cells efficiently killed the prototype NK target YAC-1. However, against other targets, killing was more variable. First, while STSC-derived NK cells clearly distinguished MHC class I(-) from MHC class I(+) tumor cell targets, LTBMC-derived NK cells did not; they either killed both targets equally well or not at all. Secondly, LTBMC-derived NK cells were largely incapable of killing lymphoblast targets deficient in MHC class I expression. To test whether this cytotoxic defect was due to the low number of Ly49(+) NK cells in the LTBMC, we separated Ly49(+) and Ly49(-) NK cells by cell sorting and tested them individually. This experiment showed that only Ly49(+) NK cells in the LTBMC were able to kill MHC class I(-) lymphoblasts (and to distinguish them from MHC class I(+)), despite good cytotoxicity against YAC-1 cells in both populations. These data suggest that certain modes of NK cell triggering are dependent on Ly49 receptor expression. From our results, we speculate that inhibitory receptors are expressed before triggering receptors for normal self cells during NK cell development, which may be an important mechanism to preserve self tolerance during the early stages of NK cell maturation.
Collapse
Affiliation(s)
- J Lindberg
- Microbiology and Tumor Biology Center (MTC), Karolinska Institute, Box 280, 17177 Stockholm, Sweden
| | | | | |
Collapse
|